Association of Remitting Seronegative Symmetrical Synovitis with Pitting Edema, Polymyalgia Rheumatica, and Adenocarcinoma of the Prostate by Emamifar, Amir et al.
Syddansk Universitet
Association of Remitting Seronegative Symmetrical Synovitis with Pitting Edema,
Polymyalgia Rheumatica, and Adenocarcinoma of the Prostate
Emamifar, Amir; Hess, Søren; Gildberg-Mortensen, Rannveig; Jensen Hansen, Inger Marie
Published in:
American Journal of Case Reports
DOI:
10.12659/ajcr.895717
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Emamifar, A., Hess, S., Gildberg-Mortensen, R., & Jensen Hansen, I. M. (2016). Association of Remitting
Seronegative Symmetrical Synovitis with Pitting Edema, Polymyalgia Rheumatica, and Adenocarcinoma of the
Prostate. American Journal of Case Reports, 17, 60-64. DOI: 10.12659/ajcr.895717
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Received: 2015.08.20
Accepted: 2015.11.10
Published: 2016.02.03
 1473   1   1   17
Association of Remitting Seronegative 
Symmetrical Synovitis with Pitting Edema, 
Polymyalgia Rheumatica, and Adenocarcinoma of 
the Prostate
 AEF 1 Amir Emamifar
 AEF 2 Soeren Hess
 EF 1 Rannveig Gildberg-Mortensen
 AEF 1 Inger Marie Jensen Hansen
 Corresponding Author: Amir Emamifar, e-mail: Amir.Emamifar@rsyd.dk
 Conflict of interest: None declared
 Patient: Male, 83
 Final Diagnosis: Remitting seronegative symmetrical synovitis with pitting edema
 Symptoms: Morning stiffness • pitting edema of the hands • shoulder and hip pain
 Medication: —
 Clinical Procedure: 18FDG PET/CT
 Specialty: Rheumatology
 Objective: Rare disease
 Background: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare condition that occurs in el-
derly individuals. It can present alone or in association with various rheumatic or malignant diseases.
 Case Report: An 83-year-old man presented with anemia, hyper-sedimentation, and pitting edema of the back of the hands. 
The patient complained of pain and stiffness of the shoulder and hip girdles, especially in the morning. He was 
previously diagnosed with adenocarcinoma of the prostate. After 3 years of watchful waiting, treatment with 
goserelin, a gonadotropin releasing hormone agonist, was started, when PSA had increased to 67.9 µg/l. About 
1 year before the cancer treatment, the patient also presented with sore and swollen hands, compatible with 
RS3PE, which remitted after a few months of prostatic cancer treatment. Thorough laboratory evaluation was 
performed upon admission to the Rheumatology Department and he was referred for FDG PET/CT on suspi-
cion of metastases of the previously diagnosed prostatic cancer. PET/CT imaging revealed increased FDG up-
take in the soft tissues around the shoulders and hips, but no evidence of bone metastasis or other malignant 
findings. A diagnosis of polymyalgia rheumatica (PMR) together with RS3PE syndrome was made and treat-
ment with prednisolone 15 mg/d was started, which resulted in rapid resolution of the symptoms.
 Conclusions: Presence of RS3PE in relation with PMR and prostatic cancer in our patient suggests a common trigger factor. 
To the best of our knowledge, this is the first report of a case of RS3PE that presented twice with 2 different 
diagnoses in the same patient.
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Background
Remitting seronegative symmetrical synovitis with pitting ede-
ma (RS3PE) is a rare condition that has been reported as a 
paraneoplastic syndrome [1], frequently together with pros-
tate, stomach, and colon cancers [2]. It occurs in elderly indi-
viduals and is characterized by symmetrical distal synovitis, 
pitting edema of the dorsum of the hands, and seronegativi-
ty of rheumatoid factor. It responds well to low-dose steroids 
and remains in remission for a long time unless associated 
with malignancy [2,3].
Polymyalgia rheumatica (PMR) is characterized by inflam-
matory pain and stiffness of the shoulder and pelvic girdles, 
with biochemical evidence of inflammation. It occurs most 
frequently in patients over 50 years of age [4]. However, clin-
ical diagnosis of PMR is rather difficult due to the large dif-
ferential diagnosis that can mimic PMR [5]. Although malig-
nant diseases can present with PMR-like syndrome, physicians 
should be aware of co-occurrence of both conditions at the 
same time. Here, we report the case of an 83-year-old man 
who presented twice with RS3PE; first as a paraneoplastic 
syndrome with adenocarcinoma of prostate and then with 
concurrent PMR.
Case Report
An 83-year-old man was referred to the Rheumatology 
Department due to anemia, hyper-sedimentation, and pitting 
edema of the back of the hands. The patient complained of 
pain and stiffness of the shoulder and hip girdles, especially in 
the morning. On physical examination the patient had normal 
range of motion of the shoulder, but range of motion of the hip 
was limited. There were signs of arthritis in the left knee. He 
had no symptoms or signs of headache, visual problems, jaw 
claudication, scalp tenderness, or any other cranial symptoms. 
The patient had been diagnosed with adenocarcinoma of the 
prostate 4 years before the presentation of these symptoms. 
Prostate-specific antigen (PSA) and Gleason score were 16 µg/l 
and 5 (2+3), respectively, at that point of time. He was under 
watchful waiting for 3 years until the PSA increased to 67.9 µg/l. 
This triggered initiation of hormonal ablation. Therefore, treat-
ment with injection of goserelin 10.8 mg every 3 months, to-
gether with bicalutamide 150 mg/day in the first 2 weeks, was 
started. After 9 months, treatment was changed to leuprorelin 
every 6 months and the PSA level decreased to less than 0.1 
µg/l within 3 months after treatment. One year before the ini-
tiation of treatment with goserelin, the patient also had sore 
and swollen hands, compatible with RS3PE. This phenomenon 
disappeared when PSA level fell to 0.3 µg/l.
Laboratory test Reference value Patient’s value
Hemoglobin 8–11 mmol/l 5.7 mmol/l
Mean cell volume 80–100 fl 86 fl
Reticulocytes 35–100×10E9/l 51×10E9/l
Iron 9–35 µmol/l 3.7 µmol/l
Transferrin 24.4–41.0 µmol/l 25.7 µmol/l
Ferritin 15–300 µg/l 404 µg/l
Haptoglobin 0.47–2.05 g/l 3.39 g/l
Folate 5–30 nmol/l 8.6 nmol/l
Cobalamin 140–650 pmol/l 220 pmol/l
Urate 0.20–0.45 mmol/l 0.26 mmol/l
Erythrocyte sedimentation rate <20 mm/hr 106 mm/hr
C-reactive protein <10 mg/l 100 mg/l
PSA (prostate-specific antigen) 0.1 µg/l <5.00 µg/l
IgM rheumatoid factor <15 IU/mL Negative
Anti ccp (anti-cyclic citrullinated peptide antibody) <20.0 U Negative
ANA (antinuclear antibody) £1.0 U Negative
Jo-1 antibody <1.0 U Negative
Table 1.  Results of laboratory tests at admission to the department of rheumatology, approximately one year after initiation of 
prostatic cancer treatment.
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Results of laboratory evaluations are summarized in Table 1. 
The patient was anemic and the levels of erythrocyte sedimen-
tation rate and C-reactive protein had increased. Bone marrow 
aspiration was done to rule out hematological malignancy or 
bone metastasis; results were normal and demonstrated nor-
mal surface antigen with normal karyotype. The result of pe-
ripheral blood smear showed hypochromic erythrocytes with 
a slight increase in nucleated blood cells without immature 
or plasma cells. The patient was referred for FDG PET/CT scan 
due to suspicion of metastases. FDG PET/CT is a routine exam-
ination in cases of suspected occult cancer or suspected me-
tastases from known cancer, as well as to identify causes of 
rheumatologic diseases [6]. The results of FDG PET/CT imaging 
visualized a strong FDG uptake in the soft tissues around the 
shoulders and hips, consistent with PMR (Figure 1). There was 
no evidence of bone metastases and no other findings suspi-
cious for malignancies. Therefore, the patient was referred to 
the Rheumatology Department due to suspicion of an under-
lying rheumatologic condition. Ultrasound-guided puncture of 
the left knee was done to determine the cause of swelling in 
the affected joint, and the result showed a small increase in 
leucocytes (860×10E6/l, normal range <200×10E6/l)) with no 
evidence of crystal deposition, which was compatible with ar-
throsis. Temporal artery biopsy was performed to diagnose a 
possible inflammation and the result was negative. Treatment 
with prednisolone 15 mg/d was started with a tapering sched-
ule of reducing 2.5 mg every 2 weeks. Ca-vitamin D supple-
mentation and alendronate 70 mg every week were addition-
ally prescribed to reduce the risk of osteoporosis. The patient 
became asymptomatic after a short period of time and all sub-
sequent biochemistry test results were normal. Decreasing 
the prednisolone dosage to 5 mg/d resulted in recurrence of 
symptoms and slight increase in CRP value. As a result, pred-
nisolone dosage was increased to 12.5 mg/d again, whereup-
on symptoms disappeared, and that was successfully tapered 
afterward. The prednisolone medication was ceased after 18 
months, without any related adverse effects. After 4-year fol-
low-up in the Rheumatology Department and 8 years after 
cancer diagnosis, the patients is still alive and has no symp-
toms or signs of PMR or RS3PE, without having any evidence 
of cancer recurrence, and PSA level has remained undetect-
able (PSA <0.1 µg/l). He also has no complaints of pain in the 
left knee and recently started to exercise at a gym.
Discussion
RS3PE is a rare condition in the elderly and can appear as a 
first presentation of various types of rheumatic and malignant 
diseases. It is first described by McCarthy et al. [7] in 1985. 
The etiology of the RS3PE syndrome is unknown, but envi-
ronmental factors and infection may affect the course of the 
disease. It can present alone or in association with rheumatic 
diseases (e.g., PMR and late-onset rheumatoid arthritis) and 
malignancies [8,9]. Diagnosis is based on clinical features. 
Absence of erosive or degenerative changes plus dramatic re-
sponse to low-dose corticosteroid treatment is characteristic 
of the disease [10].
PMR is the most common rheumatic disease in older individu-
als. It is difficult to diagnose PMR due to the wide variation in 
Figure 1.  Fused coronal FDG-PET/CT scan of the patient 
suspected of having malignancy and RS3PE syndrome. 
Diffusely increased FDG uptake in soft tissue around 
the shoulder and hip girdles (white arrows) and 
FDG-positive axillary lymph nodes (not shown) were 
suggestive of polymyalgia rheumatica. Physiologic FDG 
uptake can be seen in the liver and the urinary tract, 
but there were no other pathologic findings (i.e., no 
evidence of bone metastases and no lesions suspicious 
of malignancy). The scan was performed according 
to the Department of Nuclear Medicine’s standard 
procedure, which follows guidelines from the European 
Association of Nuclear Medicine. CT was performed as 
a low-dose scan without contrast enhancement.
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clinical picture. In addition, there are no specific tests available 
for PMR. Presenting symptoms, including proximal pain and 
stiffness, a commonly accepted characteristic of PMR, are not 
indicative of PMR and can occur in other rheumatologic diseas-
es. However, distal manifestations, such as peripheral arthritis 
and carpal tunnel syndrome, present in half of PMR cases [11].
Treatment with glucocorticoids is a mainstay and it results in 
rapid resolution of symptoms [11,12]. The British Society for 
Rheumatology and British Health Professionals in Rheumatology 
recommend use of prednisolone 15 mg/d when the diagnosis 
is established. Subsequently, the dosage should be gradual-
ly tapered over time. All patients diagnosed with PMR should 
commence calcium and vitamin D supplementation to reduce 
risk of osteoporosis [12].
Several previous studies reported a PMR-like syndrome as a 
presenting manifestation of various malignant diseases (e.g., 
prostate cancer [5,13,14], renal cell carcinoma [15], and lym-
phoma [16]). Other malignancies mimicking PMR include can-
cers of the gastrointestinal system, lungs, pancreas, uterus, and 
ovaries [5]. However, PMR patients have an increased risk of 
malignancies. A recent cohort study by Muller et al. [4] showed 
a 69% increased risk of malignancies in PMR patients within 
the first 6 months after a PMR diagnosis. When our patient 
was referred with suspected PMR, it was obvious to suspect a 
condition like metastatic prostate cancer mimicking PMR, but 
this was not shown by the FDG PET/CT scan. The subsequent 
diagnosis of PMR concurrent with RS3PE was seen as an inde-
pendent phenomenon. Since PMR and RS3PE presented and 
disappeared almost at the same time, it can be assumed that 
there is an association between them.
RS3PE may present before, concurrent with, or after the diag-
nosis of malignant disease. In our case the RS3PE syndrome 
presented approximately 1 year before prostate cancer was 
estimated to need treatment, and the syndrome disappeared 
again after about 6 months of cancer treatment, which sug-
gests a correlation between these 2 conditions. Considering 
the long disease history of prostate cancer, it might reason-
ably be assumed that the patient had been suffering from 
prostatic cancer for a very long time before the diagnosis. If 
the prostatic cancer was the triggering factor for RS3PE (in 
this case, when tumor burden was large enough), one could 
speculate that there are potential immunological mechanisms 
triggering RS3PE.
Conclusions
This report illustrates a rare case of RS3PE that occurred to-
gether with PMR and prostate cancer. Presence of RS3PE first, 
simultaneously with prostatic cancer, as a paraneoplastic syn-
drome, and thereafter concurrent with clinical presentation of 
PMR, suggests a common trigger factor for RS3PE from a pros-
tatic cancer and PMR. It has previously been reported that there 
is an association between prostatic cancer and PMR as well 
as RS3PE. On the other hand, RS3PE was found to be correlat-
ed with prostatic cancer and PMR [10,13,17]. However, in the 
presented case prostatic cancer and PMR were seen together 
with RS3PE, although not at the same time. In line with earli-
er studies, our case report suggests that PMR and RS3PE be-
long to the same clinical entity. To the best of our knowledge, 
this is the first case report of RS3PE presenting twice in 2 dif-
ferent diagnoses in the same patient.
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